Phase II study of a longitudinal rehabilitation program for allogeneic blood and marrow transplantation patients.

Allogeneic blood and marrow transplantation (alloBMT) is a curative treatment for blood cancers associated with various treatment-related adverse events and morbidities for which rehabilitation programs are currently limited. A Phase II randomized controlled trial (RCT) was conducted to assess the feasibility, acceptability, and impact of CaRE-4-alloBMT: a longitudinal multidimensional cancer rehabilitation program for patients undergoing alloBMT. Primary outcomes included the feasibility and acceptability of the intervention and methods. Feasibility was assessed through recruitment, retention, and adherence rates. Acceptability was assessed through qualitative interviews. Secondary clinical outcomes were collected through questionnaires and physiological assessments at four time points. A total of 80 participants were recruited and randomized. Recruitment (72%) and retention (70%) rates, along with qualitative findings, support the feasibility of the intervention. Adherence was suboptimal, most notably educational module completion (22.7%). Treatment effect sizes of 0.70, 95% CI [0.20, 1.21] (30-second sit-to-stand test), and 0.46, 95% CI [-0.17, 1.09] (SF-36) were observed in favour of the intervention. Results appear promising; however, findings are limited by missing data from attrition. Modifications will be required to refine the program and inform a Phase III RCT. (NCT04966156).
(Copyright © 2024 American Society of Hematology.)